	Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study. Sci Rep Roviello G, Gambale E, Giorgione R, Basso U, Oliveri M, Cremante M, Atzori F, Scagliarini S, Masini C, Baldazzi V, Scolari F, Mela MM, Lai E, Vascotto IA, Rossi V, Calandrelli C, Rossini D, Lavacchi D, Serni S, Minervini A, Pillozzi S, Antonuzzo L. PMID: 42321365 [PubMed - as supplied by publisher]
	Editorial Comment to Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. Int J Urol Tanaka H. PMID: 42321141 [PubMed - in process]
	Prostate Cancer Working Group 4 Recap. Eur Urol Focus Ravi Kumar AS, Hansen AR. PMID: 42321089 [PubMed - as supplied by publisher]
	Association of asymptomatic PSA testing on prostate cancer mortality; a case control study in general practice. BJGP Open Sheikh SR, Castanon A, Mathews C, Round T, Sasieni P. PMID: 42320978 [PubMed - as supplied by publisher]
	Editorial Comment to: Prognostic Significance of Pretreatment Blood-Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in Japan. Int J Urol Takamoto D. PMID: 42320956 [PubMed - in process]
	Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer. Cancer Genet Hof JP, Galesloot TE, Aben KKH, Bryan RT, Catto JWF, Cheng KK, Conroy S, Fleshner NE, van der Heijden AG, James ND, Mengual L, Uunk FM, Verhaegh G, Vrieling A, Zeegers MP, Kiemeney LALM, Vermeulen SH. PMID: 42320430 [PubMed - as supplied by publisher]
	Theranostic strategies in prostate cancer: Advances in PSMA PET imaging and radioligand therapy. Cancer Treat Res Commun Al-Assil T, Han J, Hasan N, Gibson S, Seneriches J, Kim M, Yang J, Srinivas S, Kalebasty AR. PMID: 42320339 [PubMed - as supplied by publisher]
	Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-GuÃ©rin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled cohort clinical study. Urol Oncol Zahran AA, Shokeir AA, Serria MS, Awadalla A, El-Gamal R, Elshabrawy I, Baiomy AA. PMID: 42320108 [PubMed - as supplied by publisher]
	Predicting extraperitoneal ssRARP difficulty: an MRI-based nomogram. J Robot Surg Liu J, Zhang Q, Lin F, Yue G, Huang Y, Zeng B, Cai C, Gu D, Liu Y. PMID: 42319727 [PubMed - indexed for MEDLINE]
	Platelet-Prostate cancer crosstalk driving disparities and therapeutic vulnerabilities. Discov Oncol Mariani V, Lee NH. PMID: 42319679 [PubMed - as supplied by publisher]
	Anatomy and patient comorbidity in robotic partial nephrectomy: predictors of complexity and outcomes. J Robot Surg Pumfrey N, Azhar F, Harwood R, Rahemtoola MS, Zelhof B. PMID: 42319664 [PubMed - indexed for MEDLINE]
	Digital twin technologies in prostate cancer as a frontier for precision medicine. Eur Radiol Exp Pecoraro M, Messina E, Novelli S, Laschena L, Blasilli G, Tronci E, Panebianco V. PMID: 42319650 [PubMed - indexed for MEDLINE]
	Integrative analysis of the roles and prognostic value of RNA-binding proteins in papillary renal cell carcinoma. Discov Oncol Niu T, Li Q, Zhang A. PMID: 42319639 [PubMed - as supplied by publisher]
	Tumor anatomy predictors of mic and trifecta achievement in robot-assisted partial nephrectomy: a multicenter analysis stratified by PADUA score. J Robot Surg Kanaan MR, Idais H, Faraj Tabrizi P, Schiefelbein F, Schoen G, Wiesinger C, Ubrig B, Gloger S, Nuhn P, Eraky A, Wagner C, Ayanle A, Al-Nader M, Hadaschik BA, Münden JF, Katzendorn O, Fuhrmann C, Kuczyk MA, Siemer S, Zeuschner P, Mayr R, Harke NN. PMID: 42319570 [PubMed - indexed for MEDLINE]
	Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation. Abdom Radiol (NY) Arita Y, Zheng X, Wen F, Fujiwara M, Bijari M, Glaudemans AWJM, Ruiter SJS, Lütje S, Noordzij W. PMID: 42319425 [PubMed - as supplied by publisher]
	Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. Cancer McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI. PMID: 42319132 [PubMed - indexed for MEDLINE]
	Magnetic resonance imaging-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial. Cancer Cheng Y, Huang H, Wang M, Zhu L, Peng S, Li D, Marra G, Qi R, Ding X, Liu M, Qiu X, Guo H. PMID: 42319125 [PubMed - indexed for MEDLINE]
	Primary testicular neuroendocrine tumor: Diagnostic challenges and WHO 2022 classification insights. J Int Med Res Garousi V, Khalaj F, Mirzaian E. PMID: 42319038 [PubMed - indexed for MEDLINE]
	Diagnostic performance of biparametric versus multiparametric MRI for prostate cancer: a noninferiority, confirmatory observer study. Front Oncol Fang X, Li J, Lv W, Liu L, Feng J, Liu L, Pan F, Zhang Y. PMID: 42318473 [PubMed]
	Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma. Front Pharmacol Zhu H, Lin Q, Yu Z, Huang X. PMID: 42318352 [PubMed]

Articles 1 - 20 / 179127

Page 1 of 8957



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy